Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2020 Feb 21;17(1):11.
doi: 10.1186/s12954-020-00358-3.

Prevalence of HCV among people who inject drugs in Brussels-a respondent-driven sampling survey

Luk Van Baelen  1 , Els Plettinckx  2 , Jérôme Antoine  2 , Lies Gremeaux  2
Affiliations

Prevalence of HCV among people who inject drugs in Brussels-a respondent-driven sampling survey

Luk Van Baelen et al. Harm Reduct J. .

Abstract

Background: In Belgium, people who inject drugs (PWID) are at a high risk of being infected by hepatitis C (HCV) as injecting drug use is the main mode for transmission of HCV in Europe. Estimates about the number of people living with HCV in Belgium are rare and even less is known about the prevalence of HCV among PWID.

Method: Between 1 February 2019 and 26 April 2019, PWID and high-risk opiate users (HROU) were recruited in Brussels through respondent-driven sampling (RDS). They were invited to a questionnaire and underwent a rapid HCV test.

Results: A total of 253 respondents participated in the study, of which 168 were PWID and 238 were HROU, with 153 respondents belonging to both categories. The overall unweighted sample average for HCV antibodies was 41.1%. The weighted population estimates were 43.7% (95% CI 30.6-56.8%) for RDS-II and 43.4% (95% CI 28.9-58.0%) for RDS-SS.

Conclusions: This prevalence is lower than the prevalence estimates reported elsewhere in Europe. However, the data still suggest that serious efforts are needed to reach the goal set by the WHO to reduce HCV by 2030 with 90%.

Keywords: Belgium; Hepatitis C; People who inject drugs; Prevalence.

PubMed Disclaimer

Conflict of interest statement

The authors declare that they have no competing interests.

Figures

Fig. 1
Fig. 1
Recruitment chains of RDS in Brussels, 2019. Red, seed; blue, PWID, round; non-PWID, bold; HCVab+, not bold, HCVab−
See this image and copyright information in PMC

References

    1. World Health Organization (WHO) Access to hepatitis C testing and treatment for people who inject drugs and people in prisons - a global perspective. Policy brief. Geneva: World Health Organization; 2019.
    1. ECDC . Annual epidemiological report for 2017. Hepatitis C. 2019.
    1. MatheI C, Wollants E, Verbeeck J, Van Ranst M, Robaeys G, Van Damme P, et al. Molecular epidemiology of hepatitis C among drug users in Flanders, Belgium: association of genotype with clinical parameters and with sex- and drug-related risk behaviours. Eur J Clin Microbiol Infect Dis. 2005;24:514–522. doi: 10.1007/s10096-005-1376-9. - DOI - PubMed
    1. Micalessi I, Gérard C, Ameye L, Plasschaert S, Brochier B, Vranckx R. Distribution of hepatitis C virus genotypes among injecting drug users in contact with treatment centers in Belgium, 2004-2005. J Med Virol. 2008;80:640–645. doi: 10.1002/jmv.21145. - DOI - PubMed
    1. Wiessing L, Ferri M, Grady B, Kantzanou M, Sperle I, Cullen KJ, et al. Hepatitis C virus infection epidemiology among people who inject drugs in Europe: a systematic review of data for scaling up treatment and prevention. PLoS One. 2014;9:e103345. doi: 10.1371/journal.pone.0103345. - DOI - PMC - PubMed